使用有限基数对阿尔茨海默病进行分类 物理学 神经网络
Logeshwari Dhavamani1, Sagar Vasantrao Joshi2, Pavan Kumar Varma Kothapalli3
1Department of Information Technology, St Joseph's Institute of Technology, Chennai, Tamil Nadu, India.
Microscopy research and technique
|December 20, 2024
概括
这项研究引入了一种新的深度学习方法,CAD-FBPINN,用于使用MRI扫描对阿尔茨海默氏病 (AD) 阶段进行分类. 优化的方法显著提高了识别认知障碍的准确性和精度,为早期诊断提供了有前途的工具.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 人工智能的人工智能
背景情况:
- 阿尔茨海默病 (AD) 的特点是逐渐的神经退行,导致认知能力下降.
- 使用功能磁共振成像 (fMRI) 准确分类AD阶段,在数据质量,可解释性和标准化方面面临挑战.
- 深度学习为医疗图像可靠的AD分类提供了潜在的解决方案.
研究的目的:
- 提出一种新的深度学习模型,使用有限基础物理神经网络 (CAD-FBPINN) 分类AD,以准确分类AD.
- 增强fMRI图像预处理和特征提取,以提高分类性能.
- 为了优化CAD-FBPINN模型,使用海马优化算法 (SHOA) 优化AD分期.
主要方法:
- 功能磁共振成像 (fMRI) 数据是从阿尔茨海默病神经成像计划 (ADNI) 数据集中获得的.
- 图像经过了使用反 lognormal 卡尔曼波器 (RLKF) 的预处理,并通过牛顿时间提取波量变换 (NTEWT) 进行特征提取.
- 提取的特征是使用海马优化算法 (SHOA) 优化的有限基础物理神经网络 (FBPINN) 进行分类的.
主要成果:
- 与现有方法相比,拟议的CAD-FBPINN方法在准确性,精度和负预测值 (NPV) 中显示出显著的改进.
- 具体来说,该方法比基线方法获得了更高的精度 (30.53%,23.34%,32.64%),精度 (20.53%,25.34%,29.64%) 和NPV (20.53%,25.34%,29.64%).
- 在分类各种AD阶段方面,CAD-FBPINN技术超过了DC-AD-AlexNet和PDP-ADI-GCNN等其他方法.
结论:
- 使用SHOA优化的CAD-FBPINN技术提供了一种强大而有效的方法,用于使用fMRI数据对阿尔茨海默氏病的阶段进行分类.
- 该方法解决了AD分类的关键挑战,为可靠和实际的治疗应用提供了潜力.
- 这种深度学习方法对早期检测和阿尔茨海默病的准确阶段确定有希望.
相关概念视频
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162


